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Regulation of renal kallikrein synthesis and activation by glucocorti-
coids. The effects of endogenous and exogenous glucocorticoids on
renal active and prokallikrein levels (nglmg protein) and in vivo
kallikrein synthesis rate were studied in the conscious rat. Within two
hours after low dose methyiprednisolone (MP, 0.0125 to 0.05 mg/l00 g
body wt), active kallikrein and prokallikrein fell (29.1 2.3 and 35.1
2,7 nglmg protein, respectively, compared to 38.4 3.7 and 42.7 3.4
in vehicle-treated rats, P < 0.05 or less). These changes were accom-
panied by a significant fall in prokallikrein synthesis rate relative to total
protein synthesis. The reductions in active and prokallikrein levels were
transient, dissipating by six hours. With increasing MP doses, there was
further dose-dependent reduction in active kallikrein. However, prokal-
likrein levels increased to normal as the MP dose was increased despite
continued suppression of synthesis, suggesting that prokallikrein acti-
vation was inhibited. Renal kallikrein levels were also examined in
relation to changes in endogenous glucocorticoid levels. In intact rats,
three hours after plasma corticosterone peaked (10 p.m.), active and
prokallikrein levels were 30.2 2.9 and 27.0 1.6 ng/mg protein,
respectively, compared to 36.9 2.3 and 37.2 2.6 (P < 0.005) three
hours after the corticosterone nadir (11 a.m.). Furthermore, adrenalec-
tomy increased active and prokallikrein (47.3 4.8 and 87.3 6.0
ng/mg protein, respectively), compared to levels in intact or sham-
operated rats (intact: 32.9 2.9and 54.9 5.3 ng/mg protein, P < 0.01
or less). Adrenalectomy also eliminated the diurnal changes in kal-
likrejn levels seen in intact rats. These data suggest that renal prokal-
likrein synthesis and activation are physiologically regulated by gluco-
corticoids.
Glucocorticoids have a number of recognized effects on renal
function. Administration to intact or adrenalectomized rats
increases GFR [1]. Although steroid-induced changes in GFR
may influence electrolyte and water excretion, it is clear that
glucocorticoids also directly modulate electrolyte and water
handling by the renal tubule [2—4]. Acute in vivo administration
of cortisol produces renal sodium retention, but clearance
studies suggest that glucocorticoid inhibits proximal tubule
sodium reabsorption [3, 4]. Dexamethasone acutely stimulates
NatK ATPase activity in isolated rat or rabbit distal convo-
luted tubules [5, 6], an effect that may be consistent with
sodium reabsorption. Systemic replacement of glucocorticoid
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after adrenalectomy increases renal free water clearance; how-
ever, glucocorticoid administration increases solute free water
reabsorption, a finding consistent with the direct observation
that water permeability is increased in isolated rabbit cortical
collecting tubule following dexamethasone treatment [3, 4, 7].
Several studies provide evidence that there is direct binding
of glucocorticoid within cells of the tubule. In rabbit distal
convoluted and collecting tubules, and in rat distal convoluted
tubules, autoradiography has demonstrated nuclear binding of
dexamethasone or corticosterone [8, 9]. In both species, gluco-
corticoid rather than mineralocorticoid binding predominates in
the distal convoluted tubule [8, 10]. These autoradiographic
studies are supported by the finding that the rat kidney contains
high affinity cytoplasmic receptors which bind glucocorticoid
and are transferred into the nucleus [11].
While functional and receptor binding studies suggest that
glucocorticoids have direct effects in the nephron, little infor-
mation is available on the effects of glucocorticoids on specific
proteins involved in nephron function. Na-K ATPase activ-
ity is increased by glucocorticoid treatment, but it is not known
if synthesis of this enzyme changes [6]. Only one renal protein,
cytosolic phosphoenolpyruvate carboxykinase, has been shown
to alter its synthesis rate following glucocorticoid treatment
[121.
There are several reports that glucocorticoids, in chronic or
pharmacologic doses, alter renal tissue levels or urinary excre-
tion of kallikrein [13—181. This serine protease is localized to
apical and basolateral membranes of distal connecting tubule
cells [19], and a high in vivo rate of kallikrein synthesis rate has
been demonstrated in the rat kidney [20, 21]. Kallikrein and its
kinin product are potent agonists for vectorial ion and water
transport across renal collecting tubules and cultured collecting
tubule cells [22—24]. Basolateral addition of kinins inhibits
ADH-stimulated sodium and water reabsorption in cortical
collecting tubules of rat or rabbit [23, 24]. Some evidence also
suggests that renal kallikrein and kinins may modulate tubulo-
glomerular feedback [25]. To begin to explore whether kal-
likrein may mediate some of the renal actions of glucocorticoid,
we studied the effects of acute physiologic manipulations of
glucocorticoid levels on renal active and prokallikrein levels
and kallikrein synthesis.
212
Jaffa et a!: Kallikrein regulation by glucocorticoids 213
Methods
Treatment protocols
Male Wistar rats (Charles River Breeding Laboratories, Inc.,
Wilmington, Massachusetts, USA) weighing 140 to 180 g were
used in all studies, Rats were housed 4 to 5 per cage in a
temperature and humidity controlled room with a 12-hour
light/12-hour dark cycle, and had free access to water and
regular chow. Experimental groups of rats which received
glucocorticoid were injected i.p. with methyiprednisolone (MP)
succinate (A-MethaPred, Abbott Laboratories, Chicago, Illi-
nois, USA). Methyiprednisolone was chosen because of its
very low mineralocorticoid activity. Control rats were injected
i.p. with saline diluent. In all studies of the effects of exogenous
glucocorticoid, rats were injected and killed between 9 a.m. and
2 p.m. Two to six hours after injection, rats were anesthetized
rapidly with methoxyfluorane (Metofane, Pitman-Moore, Inc.,
Washington Crossing, New Jersey, USA). The kidneys were
excised for measurements of tissue protein, kallikrein, and
kallikrein synthesis rate. To measure kallikrein synthesis rate,
rats were injected i.p. with 35S-methionine (1 iCi/g body wt,
diluted 1 iCi/pi saline, New England Nuclear, Bedford, Mas-
sachusetts, USA) 20 minutes before they were anesthetized and
killed.
In studies of adrenalectomized rats, rats underwent adrenal-
ectomy or a sham operation, recovered from anesthesia, and
were killed 24 hours later (11 a.m. or 10p.m.). Adrenalectomies
were performed through bilateral flank incisions on rats anes-
thetized with sodium brevital (5 mgIlOO g body wt). Complete-
ness of adrenalectomy was confirmed by plasma corticosterone
measurement when kidneys were harvested. Rats were anes-
thetized rapidly with methoxyfluorane and kidneys removed
immediately and prepared as described below. In diurnal
rhythm studies, rats were also killed at 11 a.m. or 10p.m.
Preparation of tissue homogenates
Each kidney was excised and immediately perfused via the
renal hilus with a hand-held syringe containing 10 ml of ice cold
saline (0.9%), then immediately frozen at —20°C until homoge-
nized. Kidneys were minced and then homogenized in 5 ml
phosphate buffered saline (PBS, 0.14 M NaCI in 0.01 M
Na2HPO4-NaH2PO4, pH 7.4) with a teflon/glass homogenizer
(15 strokes). Sodium deoxycholate was then added to the
homogenate (0.5% final concentration), followed by incubation
at 4°C for 60 minutes. The homogenate was centrifuged (27,000
g at 4°C for 45 mm) and the resulting supernatant was centrif-
ugally filtered through Sephadex G-25 (Pharmacia Inc., Piscat-
away, New Jersey, USA) to remove salts and detergent [20].
Filtered supernatant was used for kallikrein and protein assays,
and the measurements of kallikrein synthesis.
Assays
Active and prokallikrein were measured by a monoclonal
antibody-radioimmunoassay which has been previously de-
scribed in detail [20]. The specificity of this antibody for active
kallikrein has been demonstrated in tissue homogenate as well
as urine [26, 27]. Prokallikrein was determined by assaying each
sample before and after trypsin treatment, which converts
prokallikrein to active kallikrein, and subtracting the active
kallikrein content (pretreatment) from the total kallikrein (after
treatment). Kallikrein levels are expressed as ng/mg tissue
protein. Tissue homogenate protein was measured by the
method of Lowry et al [281, using bovine serum albumin as
standard. Plasma corticosterone levels were measured directly
by a radioimmunoassay, using antiserum B3-l63 (Endocrine
Sciences, Tarzana, California, USA).
Tissue kallikrein synthesis
The in vivo kallikrein synthesis rate, relative to total protein
synthesis, was measured by the method of Miller, Chao and
Margolius [21]. As described above, 35S-methionine (1 pCi/g
body wt) was injected i.p., and after 20 minutes the rats were
anesthetized, the kidneys removed and a tissue homogenate
supernatant prepared. Incorporation of 35S-methionine into
tissue kallikrein was measured by selective immunoprecipita-
tion with a polyclonal antikallikrein antiserum which recognizes
both active and prokallikrein [27]. To immunoprecipitate kal-
likrein from the homogenate supernatant, the supernatant was
first centrifuged at 27,000 g at 4°C for 90 minutes. Supernatant
retained from this centrifugation was treated with Triton X-l00,
sodium dodecyl sulfate (SDS) and EDTA (1%, 0.1% and 0.1 mM
final concentrations, respectively) and then centrifuged at
181,000 g at 4°C for 45 minutes in a Beckman ultracentrifuge.
Undiluted kallikrein antiserum (5 d/g kallikrein) was added to
duplicate aliquots of 0.8 to 1.0 ml of the resulting supernatant,
and these aliquots were incubated for 18 hours at 4°C. Another
set of duplicate aliquots was treated with nonimmune sheep
serum to measure nonspecific precipitation. After incubation,
all aliquots were centrifuged at 5000 g for 10 minutes. The
immunoprecipitate was recovered and washed twice with 1 ml
water containing the detergents listed above. After final centrif-
ugation (5000 g for 10 mm), the precipitate was dissolved in 0.2
ml of 0.1 M NaOH and transferred to a vial containing liquid
scintillation cocktail for counting of radioactivity. Radioactivity
immunoprecipitated from a tissue homogenate migrates as a
single peak on SDS-polyacrylamide gel electrophoresis, indi-
cating selective precipitation of kallikrein labelled in vivo [211.
Intrassay coefficient of variation is 5%.
To measure 35S-methionine incorporation into total protein,
duplicate aliquots (0.02 ml) of the supernatant were dissolved in
0.05 ml of 0.1 M NaOH at 37°C for 30 minutes. Bovine serum
albumin and casein hydrolysate were added to each aliquot
(0.01% and 0.2% final concentrations, respectively), which was
then treated with 0.5 ml of 10% trichloroacetic acid (TCA). The
precipitated protein, recovered after centrifugation at 4000 g at
4°C for 10 minutes, was washed twice with I ml of 5% TCA, and
after final centrifugation the pellet was dissolved in 0.2 ml of 0.1
M NaOH. This was transferred to a vial containing liquid
scintillation cocktail for counting of radioactivity. Relative
synthesis rate was calculated as the ratio of counts immunopre-
cipitated by antiserum to counts precipitated by TCA.
Statistical analysis
Data are expressed as mean SEM and were analyzed by
analysis of variance (ANOVA). After ANOVA of repeated
measurements (dose-response and time course studies), if dif-
ferences were detected, individual data sets were compared by
t-test. Dose-response data were also examined by Scheffe's
linear trend contrast analysis.
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Fig. 1. Renal tissue active (•) and prokallikrein (0) levels in rats
treated with methylprednisolone (MP). Rats (12 at each dose) were
killed four hours after i.p. injection of MP or vehicle (0 dose). Active
kallikrein showed a dose-related reduction. Prokallikrein was reduced
with the lowest dose but increased toward control levels as the dose of
MP was increased. ** p < 0.005, tP < 0.02, §P < 0.05 vs. vehicle-
treated,
Table 1. Time-dependency of glucocorticoid effects on renal
kallikrein
Kallikrein
ng/mg
protein
Time hr
0 2 6
Active 38.4 3.7 29.1 2.3" 43.9 4.9
Prokallikrein 42.7 3.4 35.1 2.7C 39.3 5.2
Total 81,1 6.2 64.1 2.8a 83.2 5.7
Rats (8 to 9 at each time point) were injected i.p. with methyipred-
nisolone (0.0125 mg/l00 g body wt) and killed 2 or 6 hours later.
Controls (0 hr) were injected with vehicle and killed immediately.
a < 0.01
' P < 0.025
P < 0.05 vs. 0 hr
Table 2. Renal kallikrein content and synthesis rate in controls and
methylprednisolone (MP)-treated rats (0.0125 or 0.05 mg/l00 g body
wt)
Control
(N= 18)
MP-treated
(N=20)
Kallikrein ng/mg protein
Active 47.3 3.2 33.5 1.4"
Prokallikrein 39.4 3.1 27.7 2.1C
Total 86.6 4.9 61.2 26b
Kallikrein synthesis ratea 2.70 0.25 2.32 0.101
Rats were injected with MP or vehicle i.p. and killed after 3 hr.
35S-methionine was injected i.p. 20 minutes before killing to label
kallikrein. The effects of 0.0125 and 0.05 mg were similar, and therefore
the data are combined.
a l03 x ratio of kallikrein cpm/mg protein to TCA-protein cpm/mg
protein
"P < 0.001, P < 0.005, d P < 0.05 vs. control
Renal kallikrein levels in MP-treated rats
Renal tissue levels of active and prokallikrein in rats treated
in the a.m. with MP (0.0125 to 12.5 mg/l00 g body wt) or vehicle
are shown in Figure 1. Measured four hours after MP, active
renal kallikrein showed a progressive dose-dependent reduc-
tion. This reduction was significant at a dose of 0.125 mg/l00 g
body weight (34.2 3.6 vs. 44.0 4.4 ng/mg protein in MP vs.
vehicle-treated, respectively, P < 0.05). The response of
prokallikrein to increasing MP doses differed. While prokal-
likrein was significantly reduced with the lowest MP dose (35.5
2.8 in MP vs. 46.0 3.7 ng/mg protein in vehicle-treated, P
< 0.02), as the dose increased, prokallikrein increased. Rats
receiving 12.5 mg/100 g showed levels similar to vehicle-treated
rats (43.6 3.6 ng/mg protein).
To characterize the time-dependency of the effects of gluco-
corticoid on renal active and prokallikrein, their levels were
measured two and six hours after injection of the lowest dose of
MP (0.0125 mg/100 g body wt). These results are shown in Table
1. After two hours, active and prokallikrein were significantly
reduced in MP-treated compared to vehicle-treated rats (0 hr).
However, after six hours, both levels had returned to normal.
Because a significant portion of kallikrein in the kidney is
membrane bound, we examined whether the reduction in
kallikrein observed following glucocorticoid treatment could be
the result of redistribution of kallikrein between cytosol and
membranes, and therefore due to a change in the amount of
kallikrein extracted by detergent treatment. In control kidneys,
more than 90% of prokallikrein and active kallikrein were
consistently extracted from kidney tissue by the first of repet-
itive extractions with deoxycholate. After the second extrac-
tion, negligible immunoreactive kallikrein could be obtained.
This was not altered by low dose (0.0125 mg/100 g) or high dose
(12.5 mg/l00 g) glucocorticoid treatment.
Renal kallikrein synthesis in MP-treated rats
Renal kallikrein synthesis was measured in rats treated with
low doses (0.0125 or 0.05 mgIlOO g body wt) or high doses (12.5
mg/tOO g) of MP. Since the above studies showed that tissue
prokallikrein was significantly reduced two to four hours after a
low dose of MP, we measured kallikrein synthesis rate and
levels three hours after MP injection. The effects of 0.0 125 and
0.05 mg were similar and therefore the combined results are
shown in Table 2. Both active and prokallikrein levels were
reduced at three hours. This was accompanied by a significant
reduction in kallikrein synthesis rate. High dose MP (12.5
mg/bOg) reduced kallikrein synthesis to a similar extent (2.40
0,13 vs. 2.91 0.19, P < 0.005). As observed in the dose-
response study, the tissue level of prokallikrein was not signif-
icantly reduced by high dose MP (22.0 2.9 vs. 30.1 3.7
nglmg protein, MP vs. vehicle, respectively). However, active
kallikrein was reduced (23.6 1.4 vs. 48.4 5.2 ng/mg protein,
P < 0.001).
Finding that renal kallikrein levels and synthesis were acutely
reduced by small doses of exogenous glucocorticoid suggested
that changes in endogenous glucocorticoid levels might have
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Fig. 2. Effects of adrenalectomy on renal active and prokallikrein.
Rats were adrenalectomized (U) or sham-operated () in the p.m. and
killed 24 hours later at 10 p.m. When rats were killed in the a.m., near
the nadir in plasma corticosterone of intact rats (D), kallikrein levels did
not differ between adrenalectomized and intact rats. * P < 0.001, tP <
0.01 vs. intact or sham-operated.
(46.2 3.2 vs. 37.6 5.4 ng/mg protein in MP-treated vs.
untreated), respectively.
Renal kallikrein levels were also compared in adrenalecto-
mized and intact rats killed at 10 to 11 a.m., when intact rats
show low plasma levels of corticosterone [291. In contrast to the
above differences observed in the p.m., adrenalectomized and
control rats killed in the a.m. did not display differences in
either active or prokallikrein (active kallikrein: 56.7 4.7 vs.
57.7 4.6 ng/mg protein; prokallikrein: 37.6 5.4 vs. 41.5
7.7 nglmg protein, adrenalectomized vs. intact, respectively).
Diurnal changes in renal kallikrein levels
similar effects. To assess this, we examined the effects of acute
adrenalectomy and the relation between diurnal rhythm in
glucocorticoid secretion and renal active and prokallikrein
levels.
Renal kallikrein levels following adrenalectomy
Adrenalectomized, sham-operated, and unoperated controls
were killed at 10 p.m. Plasma corticosterone levels were
undetectable in adrenalectomized rats, but sham-operated rats
had levels similar to intact control rats (7.32 0.57 vs. 8.09
0.74 jsgldl, sham vs. control, respectively). The kallikrein levels
from all three groups are shown in Figure 2. In adrenalecto-
mized rats, renal active and prokallikrein were increased 43%
and 59%, respectively, compared to levels in either intact or
sham-operated rats. Treatment of adrenalectomized rats with
MP (0.5 mg/100 g, midrange of the dose-response curve, Fig. 1),
reduced active kallikrein after three hours (24.9 3.3 vs. 56.7
4.7 nglmg protein in untreated adrenalectomized rats, P <
0.001). However, prokallikrein was not reduced by this dose
Figure 3 shows renal kallikrein levels in intact rats killed at
either 11 a.m., approximately three hours after their nadir in
plasma corticosterone diurnal rhythm, or at 10 p.m., three
hours after their peak corticosterone level [29]. Active and
prokallikrein levels were significantly lower in the p.m. than the
a.m. To confirm that these changes in kallikrein were due to
diurnal changes in adrenal secretion, we also measured kal-
likrein levels at 11 a.m. or 10 p.m. in adrenalectomized rats
(Table 3). Plasma corticosterone levels were undetectable in
these rats, when they were killed 22 to 31 hours after adrenal-
ectomy. There was no difference in active or prokallikrein
levels in adrenalectomized rats killed in the a.m. versus p.m.,
demonstrating that adrenalectomy eliminates the diurnal
change in kallikrein levels.
Discussion
These studies demonstrate that doses of a synthetic gluco-
corticoid, biologically equivalent to very low physiologic doses
of the rat's natural glucocorticoid [30], produce rapid and
proportional reductions in renal synthesis of kallikrein and the
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Fig. 3. Diurnal changes in renal kallikrein in intact rats. Rats were
killed at 11 a.m. or 10 p.m. Numbers of rats in each group are shown at
the bottom of the solid bars. Symbols are: (U) total; () active; (0)
prokallikrein. ** P < 0.003, §P < 0.05 vs. a.m.
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Table 3. Effect of adrenalectomy (Adx) on diurnal changes in renal
kallikrein
Adx
(a.m.)
Adx
(p.m.)
Plasma corticosterone < 1.0 < 1.0
isgidi
Renal kallikrein ng/mg protein
Active 47.2 2.9 50.0 4.9
Prokallikrein 73.3 4.7 62.0 4.9
Total 120.4 5.4 112.0 8.2
Rats (10 in each group) were killed at 11 a.m. or 10 p.m., 23 to 31
hours after adrenalectomy. In contrast to intact
adrenalectomized rats showed no diurnal change in
rats (c.f. Fig. 3),
kallikrein levels.
tissue levels of prokallikrein and active kallikrein. Furthermore,
the levels of both active enzyme and zymogen show diurnal
changes which are inverse to the diurnal cycle of plasma
corticosterone, and eliminating endogenous glucocorticoid by
adrenalectomy raises prokallikrein and active kallikrein within
24 hours. Thus, changes in glucocorticoid levels within the
physiologic range, whether endogenous or exogenous in
source, had qualitatively and quantitatively similar effects on
renal kallikrein levels. These changes in kallikrein levels (ng/mg
protein) were independent of changes in total renal protein, as
MP or adrenalectomy did not change total protein content of the
kidney (data not shown). Together, these findings strongly
suggest that tissue kallikrein in the kidney is regulated by
adrenal glucocorticoid.
The time course and the effects of different doses of gluco-
corticoid on active and prokallikrein suggest that both synthesis
and activation of prokallikrein are responsive to glucocorticoid.
Following a low dose of MP (0.0125 mg/tOO g body wt), active
kallikrein was reduced as early as two hours, but was not
significantly reduced at four hours, and by six hours had
returned to control levels (Table 1, Fig. 1). Following the same
MP dose, prokallikrein levels were significantly reduced from
two to four hours, when synthesis was also inhibited, but by six
hours levels returned to control. High dose MP inhibited
kallikrein synthesis similarly, but prokallikrein levels did not
fall and active kallikrein fell more than after the low dose. These
changes suggest that low glucocorticoid doses rapidly inhibit
synthesis and conversion of prokallikrein to active enzyme,
with activation recovering more rapidly, whereas high doses
inhibit zymogen activation to the extent that prokallikrein levels
do not fall despite a reduction in synthesis. In any case, our
direct measurements clearly show that kallikrein synthesis is
reduced by a MP dose that is less than 10% of the biologically
equivalent dose of corticosterone that normalizes plasma cor-
ticosterone levels over 24 hours in adrenalectomized rats [30].
Previous studies have not allowed a consistent conclusion
about the role of adrenal glucocorticoid in regulating renal
kallikrein. In one study of intact rats, treatment for four days
with twofold the physiologic replacement dose of corticoster-
one reduced kidney and urinary kallikrein-like enzymatic activ-
ity [13]. In another study, seven day treatment of Dahi salt-
resistant rats with dexamethasone doses equivalent to four-fold
physiologic replacement, markedly lowered urinary kallikrein-
like esterase activity [18]. A similar dexamethasone dose low-
ered urinary kallikrein-like activity after one day in normal
Wistar rats [16]. The changes observed in enzyme activity in
these studies are consistent, but results from studies of adre-
nalectomized rats have not been.
Four studies have examined the effects of adrenalectomy (3
days to 5 weeks) on rat renal kallikrein [13, 14, 17, 18]. In the
two shorter studies, renal tissue kallikrein-like activity was
reduced after three days in rats which were not given dietary
sodium supplementation [13], whereas only prokallikrein was
decreased in isolated basolateral membranes after seven days in
rats given 0.9% saline drinking water [17]. In these same studies
and in another, urinary kallikrein-like activity was reduced
three to seven days after adrenalectomy, whether extra dietary
sodium was given or not [13, 17, 31]. In contrast, Chao and
Margolius [14] found increased immunoreactive kallikrein (to-
tal) in kidney and urine after five weeks in salt-supplemented,
adrenalectomized rats.
Studies of the effects of replacing glucocorticoid in adrenal-
ectomized rats also have not shown consistent results. Very
small doses of corticosterone did not reverse the fall in urinary
kallikrein-like activity of seven day adrenalectomized rats [31],
and with tenfold the physiologic replacement dose, dexametha-
sone did not change renal kallikrein mRNA levels five days
after adrenalectomy [15]. In contrast, Noda et a! [17] found that
a large dose of dexamethasone raised the reduced prokallikrein
level of basolateral membranes isolated from kidneys of adre-
nalectomized rats. Chao and Margolius [14] observed that
cortisol replacement also reversed a change in kidney total
kallikrein following adrenalectomy, but the effect was to lower
raised levels.
The inconsistencies from assessing these studies collectively
may be related to a number of factors. First, various doses of
glucocorticoid have been given for various durations. Our
results show that active and prokallikrein levels respond tran-
siently and the changes are dose dependent, with large doses
preferentially affecting active kallikrein levels. Most studies
employed supraphysiologic doses. Moreover, chronic high
doses of glucocorticoid can have a variety of systemic effects
which may secondarily influence renal kallikrein.
Second, studies of the effects of adrenalectomy and subse-
quent steroid replacement have been carried out in rats adre-
nalectomized for several days and either given a high sodium
diet or no sodium supplementation. High sodium intake, re-
quired to sustain chronically adrenalectomized rats, may itself
have effects on renal kallikrein [32], yet lack of sodium supple-
mentation can result in hemodynamic changes which could
influence the kidney's production of kallikrein.
Since adrenalectomy also eliminates mineralocorticoid and
reduces androgen production, its effects on kallikrein could be
related to reduction in these hormones. Although chronic
mineralocorticoid excess can raise renal kallikrein, acute ad-
ministration has no effect in intact or adrenalectomized rats [33,
34]. Therefore, it is unlikely that the increased renal kallikrein
we observed in adrenalectomized rats is due to mineralocor-
ticoid deficiency. Long-term testosterone administration can
lower renal kallikrein in female rats, but has no effect in males
[14, 32], and it is unlikely that adrenalectomy reduced circulat-
ing androgen levels significantly in the male rats we studied.
Taken together with all of our data, the effects of adrenalectomy
on kallikrein can most likely be attributed to glucocorticoid
deficiency.
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Finally, because of the diurnal changes in renal kallikrein
levels that we demonstrated, the time of day which studies are
carried out could influence conclusions about glucocorticoid's
effects. During the day, when intact rats have lower glucocor-
ticoid production, kallikrein levels did not differ in adrenalec-
tomized rats and intact rats in our study. However, adrenalec-
tomized rats showed higher renal kallikrein levels in the p.m.,
when plasma corticosterone levels peaked in the intact or
sham-operated controls.
Although our studies do not define the cellular level at which
glucocorticoid regulates renal kallikrein synthesis, a recent
report described a glucocorticoid responsive element in the
5'-flanking region of the rat renal kallikrein gene [35]. Although
the significance of this with regards to regulation of gene
expression in the kidney has not been studied, two studies have
shown that glucocorticoid administration alters kallikrein
mRNA levels in other tissues. In pancreas of adrenalectomized
rats, kallikrein mRNA levels increase and dexamethasone
treatment lowers the levels [36]. Similar glucocorticoid effects
have been demonstrated on mRNA of a kallikrein-producing
pancreatic cell line [36]. In contrast, Gerald, Chao and Chao
[371 found that submandibular gland kallikrein mRNA de-
creased following adrenalectomy and rose following glucocor-
ticoid treatment. Taken together with our findings in the kidney,
these studies suggest that glucocorticoid's effects on kallikrein
regulation are tissue specific.
The physiologic significance of such regulation remains un-
clear. Increased cortical collecting duct water permeability
induced by glucocorticoid could be related to changes in
kallikrein activity, since kinins inhibit ADH-stimulated water
flow across this segment [7, 23, 24]. Relating renal hemody-
namic actions of glucocorticoid to kallikrein changes is more
difficult. Renal vasodilation has been observed following
chronic pharmacologic doses of glucocorticoid [1], but acute
physiologic doses produce no change in renal hemodynamics in
intact rats [38]. The relevance of these observations to the
reduction in kallikrein produced with acute physiologic doses is
not clear. It is interesting that while glucocorticoid rapidly
lowers tissue synthesis of kallikrein in the kidney, potentially
reducing a vasodepressor of kidney origin, renin gene expres-
sion may be increased by glucocorticoid, resulting in greater
activity of a vasopressor [39]. Data continue to accumulate
which suggest that reduced renal kallikrein activity contributes
to the pathogenesis of hypertension [40]. Therefore, our find-
ings may be relevant to the mechanisms of hypertension in-
duced by glucocorticoids [16].
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